ReviewDiabetes care2011
Limitations and future treatment options in type 2 diabetes with renal impairment.
Review in Diabetes care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04101669 (A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity
Who cites it
11 citing papers in PubMed.
- Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.Diabetologia · 2015Trial
- Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.Diabetes care · 2013Trial
- Telemedicine assists in the management of proatherogenic dyslipidemia and postprandial glucose variability in patients with type 2 diabetes mellitus: a cross-sectional study.Endocrine connections · 2021Article
- Assessment of Second-Generation Diabetes Medication Initiation Among Medicare Enrollees From 2007 to 2015.JAMA network open · 2020Article
- Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.Clinical pharmacokinetics · 2015Review
- Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.Therapeutics and clinical risk management · 2015Review
- The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Diabetes & vascular disease research · 2014Review
- Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis.Journal of the American Society of Nephrology : JASN · 2014Article
- Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Therapeutic advances in endocrinology and metabolism · 2013Article
- Diabetic nephropathy.Clinical medicine (London, England) · 2012Article
- Evaluation of Effect of Montelukast in the Model of Streptozotocin Induced Diabetic Nephropathy in Rats.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.